Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Aethlon Medical Inc. (AEMD) Readies CTE Blood Diagnostic Trial As Super Bowl LI Approaches

Super Bowl season is upon us, and every year more and more focus this time of year gets placed on a brain disease known as chronic traumatic encephalopathy (CTE). It is a disease similar to Alzheimer’s symptomatically, but is caused by repeated concussive and sub-concussive head trauma.

The movie Concussion, released late 2015, is based on the doctor who discovered the disease, Dr. Bennet Omalu and his struggle to publicize the condition in the face of opposition and stonewalling from the National Football League.

That the NFL would fight against the legitimacy of CTE as a bona fide diagnosis is unfortunate but understandable. A league fighting for its future with declining ratings should be expected to look at such accusations with suspicion. Nonetheless, it does seem indisputable that CTE is a serious football-related illness with grave consequences for sufferers and their families. Suicides and even more horrific murder-suicides committed by professional football players with confirmed CTE brain damage have occurred as recently as 2012.

The good news is that following years of fighting between the medical community and the NFL, both sides seem to be cooperating more readily on the issue as the reality of CTE becomes more known and accepted. Some minor advances have been made towards prevention, one of them being a simple U-shaped mechanism like a small airplane pillow that lightly clamps the jugular vein to gently slow blood flow out of the brain, giving brain tissue a tighter blood cushion against impact. Research has also been done on cannabis, showing that cannabinoids have neuroprotective properties that can help repair brain damage after a head injury or impact. The NFL has been considering changing its policy against medical cannabis in light of this new research.

But the main problem with the disease is that it cannot be diagnosed during life, making it virtually impossible to treat, as well as a source of nagging contention between the NFL and the medical community. CTE can only be diagnosed retroactively post-mortem, which admittedly is not very helpful for patients.

This year may change all that, with diagnostic firm Exosome Sciences, a subsidiary of Aethlon Medical, Inc. (NASDAQ:AEMD) planning a 200-patient clinical trial to begin next quarter testing former NFL players for a blood marker called plasma exosomal tau, a stable blood byproduct of brain scar tissue generated in CTE. At a planned enrollment of 200 players, it aims to be the largest clinical trial of NFL players ever conducted.

In an earlier study, 78 former NFL players were examined for this biomarker against a control group of 16 athletes of non-contact sports. What Aethlon and Exosome found ultimately was that plasma exosomal tau levels correlated with performance on memory and psychomotor tests, and that levels of this biomarker were 9 times higher in the NFL group versus the control group. Results were published in 2016 in the Journal of Alzheimer’s Disease.

Follow Aethlon Medical Inc (NASDAQ:AEMD)
Trade (NASDAQ:AEMD) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.